Raiffeisen Bank International AG Makes New Investment in United Therapeutics Co. (NASDAQ:UTHR)

Raiffeisen Bank International AG purchased a new stake in shares of United Therapeutics Co. (NASDAQ:UTHR) during the fourth quarter, HoldingsChannel reports. The institutional investor purchased 1,712 shares of the biotechnology company’s stock, valued at approximately $612,000.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Newbridge Financial Services Group Inc. bought a new position in United Therapeutics in the 4th quarter valued at approximately $25,000. Dunhill Financial LLC lifted its holdings in shares of United Therapeutics by 100.0% during the fourth quarter. Dunhill Financial LLC now owns 100 shares of the biotechnology company’s stock valued at $35,000 after purchasing an additional 50 shares in the last quarter. Millstone Evans Group LLC bought a new position in shares of United Therapeutics during the fourth quarter valued at $67,000. MassMutual Private Wealth & Trust FSB boosted its position in shares of United Therapeutics by 31.9% during the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 240 shares of the biotechnology company’s stock valued at $85,000 after buying an additional 58 shares during the last quarter. Finally, Natixis bought a new stake in United Therapeutics in the 4th quarter worth about $85,000. Institutional investors own 94.08% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on the stock. Morgan Stanley upped their target price on shares of United Therapeutics from $346.00 to $348.00 and gave the company an “equal weight” rating in a research note on Thursday, May 1st. HC Wainwright restated a “buy” rating and set a $425.00 price objective on shares of United Therapeutics in a research report on Monday, May 5th. Bank of America raised shares of United Therapeutics from an “underperform” rating to a “neutral” rating and set a $314.00 target price for the company in a research report on Monday, April 21st. JPMorgan Chase & Co. decreased their target price on shares of United Therapeutics from $355.00 to $350.00 and set an “overweight” rating for the company in a research note on Thursday, May 1st. Finally, StockNews.com downgraded United Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Friday, May 2nd. Four analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, United Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $392.00.

Insider Activity

In related news, Director Tommy G. Thompson sold 2,500 shares of United Therapeutics stock in a transaction that occurred on Monday, March 24th. The stock was sold at an average price of $318.80, for a total transaction of $797,000.00. Following the sale, the director now owns 8,480 shares of the company’s stock, valued at approximately $2,703,424. This trade represents a 22.77% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, COO Michael Benkowitz sold 10,000 shares of the business’s stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $371.05, for a total value of $3,710,500.00. Following the completion of the transaction, the chief operating officer now directly owns 2,577 shares in the company, valued at approximately $956,195.85. This represents a 79.51% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 65,500 shares of company stock worth $20,765,280 in the last three months. Company insiders own 10.30% of the company’s stock.

United Therapeutics Stock Up 0.5%

NASDAQ UTHR opened at $305.35 on Friday. United Therapeutics Co. has a 52 week low of $264.33 and a 52 week high of $417.82. The company has a market capitalization of $13.77 billion, a P/E ratio of 13.41, a price-to-earnings-growth ratio of 0.97 and a beta of 0.58. The stock’s 50-day moving average price is $299.95 and its 200-day moving average price is $340.44.

United Therapeutics (NASDAQ:UTHR) last released its earnings results on Wednesday, April 30th. The biotechnology company reported $6.63 EPS for the quarter, topping analysts’ consensus estimates of $6.29 by $0.34. The company had revenue of $794.40 million for the quarter, compared to analysts’ expectations of $726.82 million. United Therapeutics had a net margin of 40.31% and a return on equity of 19.22%. The firm’s revenue was up 17.2% compared to the same quarter last year. During the same quarter last year, the business earned $6.17 EPS. Research analysts anticipate that United Therapeutics Co. will post 24.48 EPS for the current year.

United Therapeutics Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.